BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 24531394)

  • 21. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
    Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau TH; Brown MP; Hamid O; Infante JR; Millward M; Pavlick AC; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF
    Lancet; 2012 May; 379(9829):1893-901. PubMed ID: 22608338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.
    Yaktapour N; Meiss F; Mastroianni J; Zenz T; Andrlova H; Mathew NR; Claus R; Hutter B; Fröhling S; Brors B; Pfeifer D; Pantic M; Bartsch I; Spehl TS; Meyer PT; Duyster J; Zirlik K; Brummer T; Zeiser R
    J Clin Invest; 2014 Nov; 124(11):5074-84. PubMed ID: 25329694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
    Babacan T; Türkbeyler IH; Balakan O; Pehlivan Y; Suner A; Kısacık B
    Int J Rheum Dis; 2017 Mar; 20(3):398-401. PubMed ID: 24815010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 26. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
    Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
    Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
    Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
    Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.
    Puzanov I; Amaravadi RK; McArthur GA; Flaherty KT; Chapman PB; Sosman JA; Ribas A; Shackleton M; Hwu P; Chmielowski B; Nolop KB; Lin PS; Kim KB
    Eur J Cancer; 2015 Jul; 51(11):1435-43. PubMed ID: 25980594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
    Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
    Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Massively parallel sequencing analysis of benign melanocytic naevi.
    Lozada JR; Geyer FC; Selenica P; Brown D; Alemar B; Merghoub T; Berger MF; Busam KJ; Halpern AC; Weigelt B; Reis-Filho JS; Hollmann TJ
    Histopathology; 2019 Jul; 75(1):29-38. PubMed ID: 30791119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
    D'Alonzo D; Glatz K
    Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
    [No Abstract]   [Full Text] [Related]  

  • 36. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.
    Kakavand H; Crainic O; Lum T; O'Toole SA; Kefford RF; Thompson JF; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2014 Apr; 46(3):193-8. PubMed ID: 24614711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug safety evaluation of vemurafenib in the treatment of melanoma.
    Tsai KY; Nowroozi S; Kim KB
    Expert Opin Drug Saf; 2013 Sep; 12(5):767-75. PubMed ID: 23800008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
    Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
    Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.
    Parekh V; Sobanko J; Miller CJ; Karakousis G; Xu W; Letrero R; Elenitsas R; Xu X; Elder DE; Amaravadi R; Schuchter LM; Nathanson KL; Wilson MA; Chu EY
    J Cutan Pathol; 2019 Mar; 46(3):190-194. PubMed ID: 30552700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.